The Experts below are selected from a list of 124293 Experts worldwide ranked by ideXlab platform
Faith G Davis - One of the best experts on this subject based on the ideXlab platform.
-
prevalence estimates for primary brain tumors in the united states by age Gender Behavior and histology
Neuro-oncology, 2010Co-Authors: Kimberly R Porter, Bridget J Mccarthy, Sally Freels, Faith G DavisAbstract:Despite published studies of population-based incidence, survival, and mortality, the full impact of primary brain tumors on the healthcare system in the United States has not been fully described. Although cancer prevalence is the best indicator of cancer survivorship and potential implications for long-term patient needs in the population, it is not a commonly reported measure. Few tumor registries meet the data requirements of both long-term incidence and follow-up specifically for nonmalignant brain tumors, which has frustrated efforts to estimate prevalence in a wider context.1–3 Defined as the proportion of new and existing disease cases in the population, prevalence rates represent the combined effects of disease incidence and survival. Even more importantly, they provide the basis for healthcare planning, such as decision making in drug manufacturing and research, funding for health services and research, and patient advocacy programs. These estimates are especially pertinent, because people diagnosed with brain tumors are likely to need significant supportive services. Few publications have focused on prevalence studies involving primary brain tumors. Swedish researchers published prevalence estimates for the year 1984 for all primary brain tumors.2 Population-based prevalence studies in the United States4–5 have been limited to malignant brain tumors with 1 exception. Davis et al.6 published prevalence estimates for all primary brain tumors for the year 2000, providing the first account of the magnitude of all primary brain tumors in the United States. However, the prevalence of nonmalignant tumors was grossly underestimated because of the voluntary reporting of nonmalignant brain tumors by state cancer registries at the time. Although this earlier study contributed to the description for prevalence of malignant brain tumors in the United States, dated content on nonmalignant tumors lessens its current usefulness. With the passage of the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107–260), collection of all primary brain tumors was required by law for cases diagnosed in 2004 and later. To capture this change in standardization of reporting and the subsequent improvement in incidence rate estimates, prevalence estimates for this report were calculated for the years 2004 and 2010 for all primary brain tumors using data from the Surveillance, Epidemiology, and End Results Program (SEER) and the Central Brain Tumor Registry of the United States (CBTRUS) population-based tumor registries.
-
Prevalence estimates for primary brain tumors in the United States by age, Gender, Behavior, and histology
Neuro-oncology, 2010Co-Authors: Kimberly R Porter, Bridget J Mccarthy, Sally Freels, Faith G DavisAbstract:Prevalence is the best indicator of cancer survivorshipin the population, but few studies have focused onbrain tumor prevalence because of previous data limitations.Hence, the full impact of primary brain tumors on the healthcare system in the United States is not completely described. The present study provides an estimate of the prevalence of disease in the United States, updating an earlier prevalence study. Incidence data for 2004 and survival data for 1985–2005 were obtained by the Central Brain Tumor Registry of the United States from selected regions, modeled under 2 different survival assumptions, to estimate prevalence rates for the year 2004 and projected estimates for 2010. The overall incidence rate for primary brain tumors was 18.1 per 100 000 person-years with 2-, 5-, 10-, and 20-year observed survival rates of 62%, 54%, 45%, and 30%, respectively. On the basis of the sum of nonmalignant and averaged malignant estimates, the overall prevalence rate of individuals with a brain tumor was estimated to be 209.0 per 100 000 in 2004 and 221.8 per 100 000 in 2010. The female prevalence rate (264.8 per 100 000) was higher than that in males (158.7 per 100 000). The averaged prevalence rate for malignant tumors (42.5 per 100 000) was lower than the prevalence for nonmalignant tumors (166.5 per 100 000). This study provides estimates of the 2004 (n 5 612 770) and 2010 (n 5 688 096) expected number of individuals living with primary brain tumor diagnoses in the United States, providing more current and robust estimates for aiding healthcare planning and patient advocacy for an aging US population.
Kenneth J Zucker - One of the best experts on this subject based on the ideXlab platform.
-
Increased Cross-Gender Identification Independent of Gender Role Behavior in Girls with Congenital Adrenal Hyperplasia: Results from a Standardized Assessment of 4- to 11-Year-Old Children.
Archives of sexual behavior, 2014Co-Authors: Vickie Pasterski, Kenneth J Zucker, Peter C. Hindmarsh, Ieuan A. Hughes, Carlo L. Acerini, Debra Spencer, Sharon Neufeld, Melissa HinesAbstract:While reports showing a link between prenatal androgen exposure and human Gender role Behavior are consistent and the effects are robust, associations to Gender identity or cross-Gender identification are less clear. The aim of the current study was to investigate potential cross-Gender identification in girls exposed prenatally to high concentrations of androgens due to classical congenital adrenal hyperplasia (CAH). Assessment included two standardized measures and a short parent interview assessing frequency of Behavioral features of cross-Gender identification as conceptualized in Part A of the diagnostic criteria for Gender identity disorder (GID) in the DSM-IV-TR. Next, because existing measures may have conflated Gender role Behavior with Gender identity and because the distinction is potentially informative, we factor analyzed items from the measures which included both Gender identity and Gender role items to establish the independence of the two constructs. Participants were 43 girls and 38 boys with CAH and 41 unaffected female and 31 unaffected male relatives, aged 4- to 11-years. Girls with CAH had more cross-Gender responses than female controls on all three measures of cross-Gender identification as well as on a composite measure of Gender identity independent of Gender role Behavior. Furthermore, parent report indicated that 5/39 (12.8 %) of the girls with CAH exhibited cross-Gender Behavior in all five Behavioral domains which comprise the cross-Gender identification component of GID compared to 0/105 (0.0 %) of the children in the other three groups combined. These data suggest that girls exposed to high concentrations of androgens prenatally are more likely to show cross-Gender identification than girls without CAH or boys with and without CAH. Our findings suggest that prenatal androgen exposure could play a role in Gender identity development in healthy children, and may be relevant to Gender assignment in cases of prenatal hormone disruption, including, in particular, cases of severely virilized 46, XX CAH.
-
demographics Behavior problems and psychosexual characteristics of adolescents with Gender identity disorder or transvestic fetishism
Journal of Sex & Marital Therapy, 2012Co-Authors: Kenneth J Zucker, Allison Owenanderson, Sarah J Kibblewhite, Hayley Wood, Devita Singh, Susan J. Bradley, Kathryn ChoiAbstract:This study provided a descriptive and quantitative comparative analysis of data from an assessment protocol for adolescents referred clinically for Gender identity disorder (n = 192; 105 boys, 87 girls) or transvestic fetishism (n = 137, all boys). The protocol included information on demographics, Behavior problems, and psychosexual measures. Gender identity disorder and transvestic fetishism youth had high rates of general Behavior problems and poor peer relations. On the psychosexual measures, Gender identity disorder patients had considerably greater cross-Gender Behavior and Gender dysphoria than did transvestic fetishism youth and other control youth. Male Gender identity disorder patients classified as having a nonhomosexual sexual orientation (in relation to birth sex) reported more indicators of transvestic fetishism than did male Gender identity disorder patients classified as having a homosexual sexual orientation (in relation to birth sex). The percentage of transvestic fetishism youth and mal...
-
demographics Behavior problems and psychosexual characteristics of adolescents with Gender identity disorder or transvestic fetishism
Journal of Sex & Marital Therapy, 2012Co-Authors: Kenneth J Zucker, Allison Owenanderson, Sarah J Kibblewhite, Hayley Wood, Devita Singh, Susan J. Bradley, Kathryn ChoiAbstract:This study provided a descriptive and quantitative comparative analysis of data from an assessment protocol for adolescents referred clinically for Gender identity disorder (n = 192; 105 boys, 87 girls) or transvestic fetishism (n = 137, all boys). The protocol included information on demographics, Behavior problems, and psychosexual measures. Gender identity disorder and transvestic fetishism youth had high rates of general Behavior problems and poor peer relations. On the psychosexual measures, Gender identity disorder patients had considerably greater cross-Gender Behavior and Gender dysphoria than did transvestic fetishism youth and other control youth. Male Gender identity disorder patients classified as having a nonhomosexual sexual orientation (in relation to birth sex) reported more indicators of transvestic fetishism than did male Gender identity disorder patients classified as having a homosexual sexual orientation (in relation to birth sex). The percentage of transvestic fetishism youth and male Gender identity disorder patients with a nonhomosexual sexual orientation self-reported similar degrees of Behaviors pertaining to transvestic fetishism. Last, male and female Gender identity disorder patients with a homosexual sexual orientation had more recalled cross-Gender Behavior during childhood and more concurrent cross-Gender Behavior and Gender dysphoria than did patients with a nonhomosexual sexual orientation. The authors discuss the clinical utility of their assessment protocol.
-
the Gender identity Gender dysphoria questionnaire for adolescents and adults further validity evidence
Journal of Sex Research, 2010Co-Authors: Devita Singh, Joseph J Deogracias, Laurel L Johnson, Allison Owenanderson, Sarah J Kibblewhite, Heino F L Meyerbahlburg, Susan J. Bradley, Michele Petersonbadali, Kenneth J ZuckerAbstract:This study aimed to provide further validity evidence for the dimensional measurement of Gender identity and Gender dysphoria in both adolescents and adults. Adolescents and adults with Gender identity disorder (GID) were compared to clinical control (CC) adolescents and adults on the Gender Identity/Gender Dysphoria Questionnaire for Adolescents and Adults (GIDYQ-AA), a 27-item scale originally developed by Deogracias et al. (2007). In Study 1, adolescents with GID (n = 44) were compared to CC adolescents (n = 98); and in Study 2, adults with GID (n = 41) were compared to CC adults (n = 94). In both studies, clients with GID self-reported significantly more Gender dysphoria than did the CCs, with excellent sensitivity and specificity rates. In both studies, degree of self-reported Gender dysphoria was significantly correlated with recall of cross-Gender Behavior in childhood-a test of convergent validity. The research and clinical utility of the GIDYQ-AA is discussed, including directions for further research in distinct clinical populations.
-
Epidemiology of Gender identity disorder: Recommendations for the Standards of Care of the World Professional Association for TransGender Health.
International Journal of Transgenderism, 2009Co-Authors: Kenneth J Zucker, Anne A. LawrenceAbstract:ABSTRACT Formal epidemiological studies on the incidence and prevalence of Gender identity disorder (GID) or transsexualism have not been conducted. Accordingly, crude estimates of prevalence have had to rely on indirect methods, such as parental endorsement of Behavioral items pertaining to GID on omnibus questionnaires for children and youth or the number of adult patients seeking contra-sex hormonal treatment or sex-transformative surgery at hospital- or university-based Gender clinics. Data from child and adolescent parent-report questionnaires show that the frequent wish to be of the other sex is quite low but that periodic cross-Gender Behavior is more common. In the general population, cross-Gender Behavior is more common in girls than it is in boys but boys are referred to Gender identity clinics more frequently than are girls. Prevalence estimates of GID in adults indicate that it is higher in natal males than in natal females although this may be accounted for by between-sex variation in sexual ...
Kimberly R Porter - One of the best experts on this subject based on the ideXlab platform.
-
prevalence estimates for primary brain tumors in the united states by age Gender Behavior and histology
Neuro-oncology, 2010Co-Authors: Kimberly R Porter, Bridget J Mccarthy, Sally Freels, Faith G DavisAbstract:Despite published studies of population-based incidence, survival, and mortality, the full impact of primary brain tumors on the healthcare system in the United States has not been fully described. Although cancer prevalence is the best indicator of cancer survivorship and potential implications for long-term patient needs in the population, it is not a commonly reported measure. Few tumor registries meet the data requirements of both long-term incidence and follow-up specifically for nonmalignant brain tumors, which has frustrated efforts to estimate prevalence in a wider context.1–3 Defined as the proportion of new and existing disease cases in the population, prevalence rates represent the combined effects of disease incidence and survival. Even more importantly, they provide the basis for healthcare planning, such as decision making in drug manufacturing and research, funding for health services and research, and patient advocacy programs. These estimates are especially pertinent, because people diagnosed with brain tumors are likely to need significant supportive services. Few publications have focused on prevalence studies involving primary brain tumors. Swedish researchers published prevalence estimates for the year 1984 for all primary brain tumors.2 Population-based prevalence studies in the United States4–5 have been limited to malignant brain tumors with 1 exception. Davis et al.6 published prevalence estimates for all primary brain tumors for the year 2000, providing the first account of the magnitude of all primary brain tumors in the United States. However, the prevalence of nonmalignant tumors was grossly underestimated because of the voluntary reporting of nonmalignant brain tumors by state cancer registries at the time. Although this earlier study contributed to the description for prevalence of malignant brain tumors in the United States, dated content on nonmalignant tumors lessens its current usefulness. With the passage of the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107–260), collection of all primary brain tumors was required by law for cases diagnosed in 2004 and later. To capture this change in standardization of reporting and the subsequent improvement in incidence rate estimates, prevalence estimates for this report were calculated for the years 2004 and 2010 for all primary brain tumors using data from the Surveillance, Epidemiology, and End Results Program (SEER) and the Central Brain Tumor Registry of the United States (CBTRUS) population-based tumor registries.
-
Prevalence estimates for primary brain tumors in the United States by age, Gender, Behavior, and histology
Neuro-oncology, 2010Co-Authors: Kimberly R Porter, Bridget J Mccarthy, Sally Freels, Faith G DavisAbstract:Prevalence is the best indicator of cancer survivorshipin the population, but few studies have focused onbrain tumor prevalence because of previous data limitations.Hence, the full impact of primary brain tumors on the healthcare system in the United States is not completely described. The present study provides an estimate of the prevalence of disease in the United States, updating an earlier prevalence study. Incidence data for 2004 and survival data for 1985–2005 were obtained by the Central Brain Tumor Registry of the United States from selected regions, modeled under 2 different survival assumptions, to estimate prevalence rates for the year 2004 and projected estimates for 2010. The overall incidence rate for primary brain tumors was 18.1 per 100 000 person-years with 2-, 5-, 10-, and 20-year observed survival rates of 62%, 54%, 45%, and 30%, respectively. On the basis of the sum of nonmalignant and averaged malignant estimates, the overall prevalence rate of individuals with a brain tumor was estimated to be 209.0 per 100 000 in 2004 and 221.8 per 100 000 in 2010. The female prevalence rate (264.8 per 100 000) was higher than that in males (158.7 per 100 000). The averaged prevalence rate for malignant tumors (42.5 per 100 000) was lower than the prevalence for nonmalignant tumors (166.5 per 100 000). This study provides estimates of the 2004 (n 5 612 770) and 2010 (n 5 688 096) expected number of individuals living with primary brain tumor diagnoses in the United States, providing more current and robust estimates for aiding healthcare planning and patient advocacy for an aging US population.
Bridget J Mccarthy - One of the best experts on this subject based on the ideXlab platform.
-
prevalence estimates for primary brain tumors in the united states by age Gender Behavior and histology
Neuro-oncology, 2010Co-Authors: Kimberly R Porter, Bridget J Mccarthy, Sally Freels, Faith G DavisAbstract:Despite published studies of population-based incidence, survival, and mortality, the full impact of primary brain tumors on the healthcare system in the United States has not been fully described. Although cancer prevalence is the best indicator of cancer survivorship and potential implications for long-term patient needs in the population, it is not a commonly reported measure. Few tumor registries meet the data requirements of both long-term incidence and follow-up specifically for nonmalignant brain tumors, which has frustrated efforts to estimate prevalence in a wider context.1–3 Defined as the proportion of new and existing disease cases in the population, prevalence rates represent the combined effects of disease incidence and survival. Even more importantly, they provide the basis for healthcare planning, such as decision making in drug manufacturing and research, funding for health services and research, and patient advocacy programs. These estimates are especially pertinent, because people diagnosed with brain tumors are likely to need significant supportive services. Few publications have focused on prevalence studies involving primary brain tumors. Swedish researchers published prevalence estimates for the year 1984 for all primary brain tumors.2 Population-based prevalence studies in the United States4–5 have been limited to malignant brain tumors with 1 exception. Davis et al.6 published prevalence estimates for all primary brain tumors for the year 2000, providing the first account of the magnitude of all primary brain tumors in the United States. However, the prevalence of nonmalignant tumors was grossly underestimated because of the voluntary reporting of nonmalignant brain tumors by state cancer registries at the time. Although this earlier study contributed to the description for prevalence of malignant brain tumors in the United States, dated content on nonmalignant tumors lessens its current usefulness. With the passage of the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107–260), collection of all primary brain tumors was required by law for cases diagnosed in 2004 and later. To capture this change in standardization of reporting and the subsequent improvement in incidence rate estimates, prevalence estimates for this report were calculated for the years 2004 and 2010 for all primary brain tumors using data from the Surveillance, Epidemiology, and End Results Program (SEER) and the Central Brain Tumor Registry of the United States (CBTRUS) population-based tumor registries.
-
Prevalence estimates for primary brain tumors in the United States by age, Gender, Behavior, and histology
Neuro-oncology, 2010Co-Authors: Kimberly R Porter, Bridget J Mccarthy, Sally Freels, Faith G DavisAbstract:Prevalence is the best indicator of cancer survivorshipin the population, but few studies have focused onbrain tumor prevalence because of previous data limitations.Hence, the full impact of primary brain tumors on the healthcare system in the United States is not completely described. The present study provides an estimate of the prevalence of disease in the United States, updating an earlier prevalence study. Incidence data for 2004 and survival data for 1985–2005 were obtained by the Central Brain Tumor Registry of the United States from selected regions, modeled under 2 different survival assumptions, to estimate prevalence rates for the year 2004 and projected estimates for 2010. The overall incidence rate for primary brain tumors was 18.1 per 100 000 person-years with 2-, 5-, 10-, and 20-year observed survival rates of 62%, 54%, 45%, and 30%, respectively. On the basis of the sum of nonmalignant and averaged malignant estimates, the overall prevalence rate of individuals with a brain tumor was estimated to be 209.0 per 100 000 in 2004 and 221.8 per 100 000 in 2010. The female prevalence rate (264.8 per 100 000) was higher than that in males (158.7 per 100 000). The averaged prevalence rate for malignant tumors (42.5 per 100 000) was lower than the prevalence for nonmalignant tumors (166.5 per 100 000). This study provides estimates of the 2004 (n 5 612 770) and 2010 (n 5 688 096) expected number of individuals living with primary brain tumor diagnoses in the United States, providing more current and robust estimates for aiding healthcare planning and patient advocacy for an aging US population.
Sally Freels - One of the best experts on this subject based on the ideXlab platform.
-
prevalence estimates for primary brain tumors in the united states by age Gender Behavior and histology
Neuro-oncology, 2010Co-Authors: Kimberly R Porter, Bridget J Mccarthy, Sally Freels, Faith G DavisAbstract:Despite published studies of population-based incidence, survival, and mortality, the full impact of primary brain tumors on the healthcare system in the United States has not been fully described. Although cancer prevalence is the best indicator of cancer survivorship and potential implications for long-term patient needs in the population, it is not a commonly reported measure. Few tumor registries meet the data requirements of both long-term incidence and follow-up specifically for nonmalignant brain tumors, which has frustrated efforts to estimate prevalence in a wider context.1–3 Defined as the proportion of new and existing disease cases in the population, prevalence rates represent the combined effects of disease incidence and survival. Even more importantly, they provide the basis for healthcare planning, such as decision making in drug manufacturing and research, funding for health services and research, and patient advocacy programs. These estimates are especially pertinent, because people diagnosed with brain tumors are likely to need significant supportive services. Few publications have focused on prevalence studies involving primary brain tumors. Swedish researchers published prevalence estimates for the year 1984 for all primary brain tumors.2 Population-based prevalence studies in the United States4–5 have been limited to malignant brain tumors with 1 exception. Davis et al.6 published prevalence estimates for all primary brain tumors for the year 2000, providing the first account of the magnitude of all primary brain tumors in the United States. However, the prevalence of nonmalignant tumors was grossly underestimated because of the voluntary reporting of nonmalignant brain tumors by state cancer registries at the time. Although this earlier study contributed to the description for prevalence of malignant brain tumors in the United States, dated content on nonmalignant tumors lessens its current usefulness. With the passage of the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107–260), collection of all primary brain tumors was required by law for cases diagnosed in 2004 and later. To capture this change in standardization of reporting and the subsequent improvement in incidence rate estimates, prevalence estimates for this report were calculated for the years 2004 and 2010 for all primary brain tumors using data from the Surveillance, Epidemiology, and End Results Program (SEER) and the Central Brain Tumor Registry of the United States (CBTRUS) population-based tumor registries.
-
Prevalence estimates for primary brain tumors in the United States by age, Gender, Behavior, and histology
Neuro-oncology, 2010Co-Authors: Kimberly R Porter, Bridget J Mccarthy, Sally Freels, Faith G DavisAbstract:Prevalence is the best indicator of cancer survivorshipin the population, but few studies have focused onbrain tumor prevalence because of previous data limitations.Hence, the full impact of primary brain tumors on the healthcare system in the United States is not completely described. The present study provides an estimate of the prevalence of disease in the United States, updating an earlier prevalence study. Incidence data for 2004 and survival data for 1985–2005 were obtained by the Central Brain Tumor Registry of the United States from selected regions, modeled under 2 different survival assumptions, to estimate prevalence rates for the year 2004 and projected estimates for 2010. The overall incidence rate for primary brain tumors was 18.1 per 100 000 person-years with 2-, 5-, 10-, and 20-year observed survival rates of 62%, 54%, 45%, and 30%, respectively. On the basis of the sum of nonmalignant and averaged malignant estimates, the overall prevalence rate of individuals with a brain tumor was estimated to be 209.0 per 100 000 in 2004 and 221.8 per 100 000 in 2010. The female prevalence rate (264.8 per 100 000) was higher than that in males (158.7 per 100 000). The averaged prevalence rate for malignant tumors (42.5 per 100 000) was lower than the prevalence for nonmalignant tumors (166.5 per 100 000). This study provides estimates of the 2004 (n 5 612 770) and 2010 (n 5 688 096) expected number of individuals living with primary brain tumor diagnoses in the United States, providing more current and robust estimates for aiding healthcare planning and patient advocacy for an aging US population.